You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

Drugs in MeSH Category Cytochrome P-450 CYP2C9 Inhibitors


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms FLUCONAZOLE fluconazole TABLET;ORAL 078423-003 Mar 7, 2011 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Baxter Hlthcare Corp FLUCONAZOLE IN SODIUM CHLORIDE 0.9% fluconazole INJECTABLE;INJECTION 077947-001 May 26, 2010 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Dr Reddys Labs Sa AMIODARONE HYDROCHLORIDE amiodarone hydrochloride TABLET;ORAL 075389-003 Dec 28, 2017 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Ani Pharms FLUCONAZOLE fluconazole TABLET;ORAL 076086-004 Jul 29, 2004 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Cytochrome P-450 CYP2C9 Inhibitors Market Analysis and Financial Projection

The market dynamics and patent landscape for Cytochrome P-450 CYP2C9 inhibitors reflect a growing focus on personalized medicine, drug safety, and innovative therapeutic development. Below is a detailed analysis:


Market Dynamics

Key Players and Growth Trends

  • Leading Companies: Alvogen, Bayer AG, and Shaanxi Xiangju Pharmaceutical Co. Ltd. are prominent in advancing CYP2C9 inhibitors through clinical stages, with several drugs already approved for conditions like hyperuricemia, infectious diseases, and dermatomycoses[6].
  • Regional Dominance:
    • North America leads due to high healthcare expenditure and R&D investment.
    • Asia-Pacific (notably China) is emerging rapidly, driven by increasing pharmaceutical capabilities and TB-related demand for drugs like rifapentine[12][14].
  • Small Molecule Dominance: Over 85% of pipeline drugs are small molecules, favored for their cost-effectiveness and established formulation pipelines[6][14].

Therapeutic Applications

  • CYP2C9 inhibitors are critical in managing drug interactions and adverse effects (e.g., NSAIDs like celecoxib and anticoagulants like warfarin)[1][7][16].
  • Approved indications include dermatomycoses, hyperuricemia, and infectious diseases, with growing interest in metabolic disorders[6][14].

Challenges and Drivers

  • Adverse Drug Reactions: NSAIDs metabolized by CYP2C9 (e.g., meloxicam, piroxicam) require dose adjustments in patients with genetic polymorphisms (e.g., CYP2C9*3)[1][16].
  • Pharmacogenomics: Genetic testing for variants like CYP2C92 and 3 is becoming standard to optimize dosing[1][8][16].
  • Regulatory Pressures: The FDA emphasizes pharmacogenomic data in drug development to minimize toxicities[8].

Patent Landscape

Key Innovation Tracks

  1. Synthesis and Intermediates
    • Patents cover synthesis routes for CYP2C9 inhibitors (e.g., intermediates in ritonavir production)[2][15]. For example, US20060069042A1 claims luteolin derivatives as potent inhibitors[15].
  2. Formulation Technologies
    • Focus on liquid/solid dosage forms and polymorphs to enhance bioavailability (e.g., Sanofi’s TB drug 3HP formulation patents)[12].
  3. Biologic Approaches
    • Monoclonal antibodies (e.g., EP2000532A1) targeting CYP2C9 for diagnostic and therapeutic use, inhibiting >90% enzyme activity[18].

Strategic Patent Filings

  • Geographic Distribution: Major filings in the U.S., Germany, and China, with corporations like Abbott Laboratories dominating synthesis and formulation patents[2][14].
  • Niche Protection: Patents increasingly target narrow claims (e.g., crystalline structures, reaction conditions) to extend market exclusivity[2][12].

Emerging Technologies and Competition

  • Machine Learning: Models predicting CYP2C9 inhibition (80% accuracy) accelerate drug discovery. Recent hits include vatalanib (IC50 0.067 μM) and ticagrelor[11][17].
  • Structural Insights: Atomic-resolution models of CYP2C9-membrane interactions inform rational inhibitor design[4].
  • Collaborative R&D: Partnerships between academia and industry (e.g., SignalGene’s closed patent) highlight the shift toward precision medicine[8][14].

Future Outlook

  • Market Expansion: Expected CAGR growth driven by Asia-Pacific investments and demand for safer NSAIDs[6][14].
  • Personalized Therapies: Integration of pharmacogenomics (e.g., CPIC guidelines for NSAID dosing) will dominate clinical practice[1][16].
  • Patent Complexity: Rising litigation around combination therapies (e.g., ritonavir-isoniazid) may delay generics[12].

Key Takeaways

  • CYP2C9 inhibitors are pivotal in reducing adverse drug reactions, with a market skewed toward small molecules and personalized dosing.
  • Patent strategies prioritize synthesis intermediates and biologic agents, while machine learning reshapes discovery pipelines.
  • Regional growth in Asia-Pacific and regulatory emphasis on pharmacogenomics are critical market drivers.

"Genetic variations in CYP450 enzymes affect their metabolic activity, thus impacting the hepatic clearance, elimination half-life, and risk of adverse effects of drugs metabolized by that CYP." — *US Pharm.* 2021[1]

References

  1. https://www.uspharmacist.com/article/cyp2c9-polymorphism-and-use-of-oral-nonsteroidal-antiinflammatory-drugs
  2. https://www.wipo.int/edocs/pubdocs/en/patents/946/wipo_pub_946.pdf
  3. https://pubmed.ncbi.nlm.nih.gov/19515014/
  4. https://journals.plos.org/ploscompbiol/article?id=10.1371%2Fjournal.pcbi.1002152
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC2879957/
  6. https://synapse.patsnap.com/blog/analysis-on-the-clinical-research-progress-of-cyp2c9-inhibitors
  7. https://pubmed.ncbi.nlm.nih.gov/15822186/
  8. http://science-metrix.com/pdf/SM_2003_015_IC_Pharmacogenomics_Potential_Canada.pdf
  9. https://examine.com/glossary/cyp2c9-inhibitors/
  10. https://onlinelibrary.wiley.com/doi/10.1155/2014/150351
  11. https://pubmed.ncbi.nlm.nih.gov/35081108/
  12. https://www.treatmentactiongroup.org/wp-content/uploads/2020/03/3hp_access_roadmap_and_patent_landscape.pdf
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11280062/
  14. https://www.databridgemarketresearch.com/reports/global-cytochrome-inhibitors-market
  15. https://patents.google.com/patent/US20060069042A1/en
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC5872075/
  17. https://pubmed.ncbi.nlm.nih.gov/32221780/
  18. https://patents.google.com/patent/EP2000532A1/en
Last updated: 2025-03-24

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.